INNOVIVA, INC. Increase (Decrease) in Prepaid Expense
INNOVIVA, INC. (INVA) reported Increase (Decrease) in Prepaid Expense of -$2.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-08-05
- INNOVIVA, INC. increase (decrease) in prepaid expense for the quarter ending 2026-06-30 was -$429.00K, a 135.87% decline year-over-year.
- INNOVIVA, INC. increase (decrease) in prepaid expense for the quarter ending 2026-03-31 was -$1.88M.
- INNOVIVA, INC. increase (decrease) in prepaid expense for the quarter ending 2025-12-31 was $7.31M, a 13.16% decline year-over-year.
- INNOVIVA, INC. increase (decrease) in prepaid expense for the quarter ending 2025-09-30 was $2.81M, a 32.67% decline year-over-year.
- INNOVIVA, INC. increase (decrease) in prepaid expense for fiscal 2025 was $5.66M.
- INNOVIVA, INC. increase (decrease) in prepaid expense for fiscal 2024 was -$567.00K.
- INNOVIVA, INC. increase (decrease) in prepaid expense for fiscal 2023 was -$7.93M, a 137.14% decline from fiscal 2022.
- INNOVIVA, INC. increase (decrease) in prepaid expense for fiscal 2022 was $21.35M.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$429.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.31M 10-Q · filed 2026-08-05 | $5.00M derived: sum of 3 quarters · filed 2026-08-05 | $7.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$1.88M 10-Q · filed 2026-05-06 | $5.43M derived: sum of 2 quarters · filed 2026-05-06 | $8.23M derived: sum of 3 quarters · filed 2026-05-06 | $9.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $7.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $10.11M derived: sum of 2 quarters · filed 2026-02-25 | $11.31M derived: sum of 3 quarters · filed 2026-08-05 | $5.66M 10-K · filed 2026-02-25 |
| 2025-09-30 | $2.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.00M derived: sum of 2 quarters · filed 2026-08-05 | -$1.65M 10-Q · filed 2025-11-05 | $6.76M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$4.45M 10-Q · filed 2026-08-05 | $3.96M derived: sum of 3 quarters · filed 2026-08-05 | $8.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$5.65M 10-Q · filed 2026-05-06 | $2.76M derived: sum of 2 quarters · filed 2026-05-06 | $6.93M derived: sum of 3 quarters · filed 2026-05-06 | -$1.14M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $8.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $12.58M derived: sum of 2 quarters · filed 2026-02-25 | $4.51M derived: sum of 3 quarters · filed 2026-02-25 | -$567.00K 10-K · filed 2026-02-25 |
| 2024-09-30 | $4.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$3.90M derived: sum of 2 quarters · filed 2025-11-05 | -$8.98M 10-Q · filed 2025-11-05 | -$2.08M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$8.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$13.15M 10-Q · filed 2025-08-06 | -$6.25M derived: sum of 3 quarters · filed 2026-02-25 | -$12.05M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$5.08M 10-Q · filed 2025-05-07 | $1.82M derived: sum of 2 quarters · filed 2026-02-25 | -$3.98M derived: sum of 3 quarters · filed 2026-02-25 | -$7.57M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $6.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.09M derived: sum of 2 quarters · filed 2026-02-25 | -$2.49M derived: sum of 3 quarters · filed 2026-02-25 | -$7.93M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$5.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$9.39M derived: sum of 2 quarters · filed 2024-11-06 | -$14.83M 10-Q · filed 2024-11-06 | $6.80M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$3.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | -$9.02M 10-Q · filed 2024-07-31 | $12.60M derived: sum of 3 quarters · filed 2025-02-26 | $15.29M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$5.44M 10-Q · filed 2024-05-08 | $16.19M derived: sum of 2 quarters · filed 2025-02-26 | $18.88M derived: sum of 3 quarters · filed 2025-02-26 | $17.25M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $21.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $24.32M derived: sum of 2 quarters · filed 2025-02-26 | $22.70M derived: sum of 3 quarters · filed 2025-02-26 | $21.35M 10-K · filed 2025-02-26 |
| 2022-09-30 | $2.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $1.07M derived: sum of 2 quarters · filed 2023-11-01 | -$277.00K 10-Q · filed 2023-11-01 | $290.00K derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | -$1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$2.97M 10-Q · filed 2023-08-02 | -$2.40M derived: sum of 3 quarters · filed 2024-03-05 | -$2.59M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | -$1.34M 10-Q · filed 2023-05-09 | -$778.00K derived: sum of 2 quarters · filed 2024-03-05 | -$970.00K derived: sum of 3 quarters · filed 2024-03-05 | -$1.30M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $567.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05 | $375.00K derived: sum of 2 quarters · filed 2024-03-05 | $40.00K derived: sum of 3 quarters · filed 2024-03-05 | -$203.00K 10-K/A · filed 2024-03-05 |
| 2021-09-30 | -$192.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$527.00K derived: sum of 2 quarters · filed 2022-11-09 | -$770.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$335.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | -$578.00K 10-Q · filed 2022-07-27 | ||
| 2021-03-31 | -$243.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $678.00K 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |